“Because of concerns about side effects, the European Medicines Agency did not approve tofacitinib for treatment of rheumatoid arthritis. The US Food and Drug Administration has approved the 5 mg dose for rheumatoid arthritis, but the package insert warns about serious infections and malignancy,” he adds.
Pfizer Inc. sponsored the trial, employed seven of the 15 authors, and had various relationships with five of the other authors.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Bachelez did not respond to a request for comments.